SCHEMBL5881848

SCHEMBL5881848

CCCCCS(=O)(=O)NC(=O)c1ccc2[nH]c(C)c(Cc3ccc(C=Cc4ccccc4)cc3)c2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 1/20 0.46
PTPN5 P54829 1/20 0.46
POLB P06746 1/20 0.42
MMP3 P08254 1/20 0.42
MMP7 P09237 1/20 0.42
MMP12 P39900 1/20 0.42
CNR1 P21554 1/20 0.40
TBXAS1 P24557 1/20 0.39
MAPT P10636 3/20 0.39
PPARG P37231 1/20 0.38
RORC P51449 1/20 0.38
HDAC3 O15379 3/20 0.38
HDAC1 Q13547 3/20 0.38
HDAC2 Q92769 3/20 0.38
NCOR2 Q9Y618 2/20 0.38
TP53 P04637 1/20 0.38
MCL1 Q07820 2/20 0.38
KDM4E B2RXH2 1/20 0.38
PSMD14 O00487 1/20 0.38
RECQL P46063 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5881846 1.00 PTPN1 (0.46) PTPN1PTPN5POLBMMP3MMP7
SCHEMBL5881850 0.91 PTPN1 (0.57) PTPN1PTPN5POLBMMP3MMP7
SCHEMBL5881774 0.88 PPARG (0.43) PTPN1PTPN5CNR1MAPTPPARG
SCHEMBL5881778 0.88 PPARG (0.43) PTPN1PTPN5CNR1MAPTPPARG
SCHEMBL5882026 0.86 POLB (0.50) PTPN1PTPN5POLBMMP3MMP7
SCHEMBL5882152 0.82 MAPT (0.49) PTPN1PTPN5POLBCNR1MAPT
SCHEMBL5881776 0.81 PTPN5 (0.68) PTPN5POLBMMP3MMP7MMP12
SCHEMBL5881779 0.81 PTPN5 (0.68) PTPN5POLBMMP3MMP7MMP12
SCHEMBL5881755 0.80 PTPN1 (0.48) PTPN1CNR1MAPTPPARGTP53
SCHEMBL6321853 0.80 PPARG (0.42) PTPN1PTPN5MAPTPPARGTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7115647-B2 Method of inhibiting neoplastic cells with indole derivatives OSI PHARMACEUTICALS, INC. (US) 2006-10-03 US disclosed
US-20020143022-A1 Method of inhibiting neoplastic cells with indole derivatives OSI PHARMACEUTICALS, INC. 2002-10-03 US disclosed
US-6410584-B1 ANTICANCER AGENTS CELL PATHWAYS, INC. 2002-06-25 US disclosed
EP-1132087-A1 REMEDIES FOR POLYCYSTIC OVARY SYNDROME FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-09-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020143022-A1 Method of inhibiting neoplastic cells with indole derivatives IDO1, IDO2, INMT PTPN1 3024/4885PTPN5 2703/4885POLB 3300/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.